Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2011. The report discloses a specific corporate transaction regarding a notifiable share interest in Theravance, Inc., rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing does not provide data on GSK's overall revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to a specific equity purchase:
- Transaction Date: August 2, 2011
- Shares Purchased: 102,466 shares of Theravance, Inc. Common Stock
- Price Per Share: $19.71
- Total Investment: $2,019,604.86
Material Changes
As a result of the transaction, GSK's total ownership in Theravance, Inc. increased to 15,667,542 shares. This represents approximately 19.01% of Theravance's outstanding capital stock (based on 82,417,371 total shares outstanding). The purchase was executed to maintain GSK's ownership percentage following net option exercises and equity vesting activity in the preceding quarter.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the share purchase. The document states that this purchase is disclosable under SEC rules.
Investor Verification Points
- Verify the current ownership percentage of GSK in Theravance, Inc. (stated as 19.01% post-transaction).
- Confirm the total number of Theravance shares outstanding used for the percentage calculation (82,417,371).
- Note that this filing does not contain GSK's quarterly or annual financial performance metrics.